There is no single universal HPV test for everyone. For women and people with a cervix, highly accurate screening tests can detect high-risk HPV strains from a cervical or vaginal sample, catching infections that could lead to cancer years before symptoms appear. For men, there is currently no FDA-approved HPV test, though research is advancing on alternatives like urine-based detection. How HPV is found depends on where in the body the virus lives, your sex, and your risk factors.
Cervical HPV Screening: Who Gets Tested and When
Routine HPV screening is built around cervical cancer prevention. The U.S. Preventive Services Task Force recommends the following schedule:
- Ages 21 to 29: A Pap smear (cervical cytology) every 3 years. HPV testing alone is not recommended in this age group because HPV infections are extremely common in younger people and almost always clear on their own.
- Ages 30 to 65: Three options, any of which is acceptable. A Pap smear every 3 years, a high-risk HPV test alone every 5 years, or both tests together (co-testing) every 5 years.
After age 65, most people can stop screening entirely if their prior results have been normal. The wider testing interval for HPV-based screening reflects the test’s high sensitivity. It catches problems earlier, so you don’t need it as often.
What HPV Tests Actually Detect
FDA-approved HPV tests screen for up to 14 high-risk strains, including HPV 16 and 18, which cause the majority of HPV-related cancers. The tests fall into two main categories.
DNA-based tests look for the genetic material of the virus itself. They can confirm that a high-risk HPV strain is present in your cells, but they can’t tell the difference between an infection your body is actively fighting off and one that’s progressing toward precancerous changes. These are the most widely used tests in routine screening.
mRNA-based tests take detection a step further. Instead of just finding viral DNA, they look for specific messenger molecules (E6/E7 mRNA) that the virus produces when it’s actively hijacking your cells in ways that lead to cancer. A positive mRNA result is a stronger signal that the infection is doing real damage, not just passing through. These tests are increasingly used to help decide next steps after an abnormal screening result.
In a real-world study of over 1,000 patients, primary HPV DNA testing had a sensitivity of nearly 99% for detecting significant precancerous changes, with a specificity of about 87%. That means the test catches almost every case that matters, though it does flag some infections that would have resolved on their own. This tradeoff is why a positive HPV test doesn’t automatically mean you have cancer or precancer. It means you need closer follow-up.
What the Test Involves
A clinician-collected HPV test feels similar to a Pap smear. A small brush or swab collects cells from your cervix during a pelvic exam. The sample goes to a lab, and results typically come back within one to three weeks.
In 2024, the FDA approved self-collection for primary HPV screening in healthcare settings. This means you can swab your own vaginal canal rather than having a clinician collect a cervical sample. The self-collected sample is still processed in a lab, and guidelines now confirm it’s acceptable for routine screening in people at average risk. If you’ve had prior abnormal results or treatment for precancerous changes, a clinician-collected cervical sample is still preferred because there isn’t enough data yet on self-collection for that population.
HPV Detection in Men
No FDA-approved HPV test exists for men. This isn’t an oversight. It reflects several biological realities: HPV infections in men are almost always asymptomatic, the virus survives differently on male genital tissue than on cervical tissue, and most infections clear without causing disease. The sampling methods designed for cervical cells simply don’t translate to male anatomy.
That said, research is exploring workarounds. Scientists have tested urine samples, oral rinses, and anal swabs as potential sources for HPV detection in men. First-void urine (the initial stream when you urinate) has shown particular promise for picking up genital HPV DNA. Anal swab testing is also gaining attention: 2024 U.S. guidelines on anal cancer specifically highlighted the importance of HPV testing for early detection in high-risk groups, including men who have sex with men and people living with HIV.
For now, HPV in men is typically discovered indirectly. Genital warts are diagnosed visually by a clinician. Anal precancer can be identified through anal cytology (similar to a Pap smear but using an anal swab), followed by high-resolution examination if the result is abnormal. But there is no routine screening recommendation for the general male population.
Oral and Throat HPV
HPV-related throat cancers, particularly in the oropharynx (the base of the tongue and tonsils), are rising sharply, especially in men. Despite this, there is no approved screening test for oral HPV in people without symptoms. You cannot get a routine swab or rinse to check for throat HPV the way you can screen for cervical HPV.
When a tumor is already present, clinicians test it for HPV to guide treatment decisions. The standard approach uses a protein marker called p16 as a first-line indicator, then confirms the result with DNA or RNA testing of the tumor tissue. Detecting active viral mRNA in the tumor is considered the gold standard, because p16 alone can be misleading: studies have found that 8% to 20% of tumors that test positive for p16 don’t actually contain HPV DNA. This matters because HPV-positive throat cancers respond differently to treatment and generally have a better prognosis than HPV-negative ones.
The practical takeaway is that oral HPV is not something you can screen for at a checkup. It’s identified after symptoms appear, usually a persistent lump in the neck, difficulty swallowing, or a sore throat that doesn’t resolve.
What a Positive HPV Result Means
A positive high-risk HPV test does not mean you have cancer. Most HPV infections, even high-risk ones, are cleared by the immune system within one to two years. What a positive result does is flag that your cells need closer monitoring.
If your HPV test is positive but your Pap smear is normal, your doctor will likely recommend repeating the test in one year. If both the HPV test and Pap smear are abnormal, the next step is usually colposcopy, a closer examination of the cervix using magnification, often with a small biopsy. The goal of the entire screening process is to catch and treat precancerous changes before they become invasive cancer, and HPV testing gives clinicians a much longer lead time than cytology alone.
HPV 16 and 18 carry the highest risk, so some tests specifically identify these two strains. If your result shows one of them, your clinician may recommend colposcopy sooner rather than taking a wait-and-watch approach, even if your Pap smear looks normal.